EGFR and non-small cell lung carcinoma: The EVIDENCE trial was a phase III study designed to assess whether the adjuvant use of icotinib could improve clinical outcomes compared to standard adjuvant chemotherapy in patients with EGFR-mutant stage II-IIIA NSCLC [14].